Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients by Xiao-Na Ma, Xiao-Na Ma, Mei-Feng Shi, Mei-Feng Shi, Shiow-Ing Wang, Shiow-Ing Wang, Wei Feng, Wei Feng, Shu-Lin Chen, Shu-Lin Chen, Xiao-Qin Zhong, Xiao-Qin Zhong, Qing-Ping Liu, Qing-Ping Liu, James Cheng-Chung Wei, James Cheng-Chung Wei, James Cheng-Chung Wei, James Cheng-Chung Wei, James Cheng-Chung Wei, Chang-Song Lin, Chang-Song Lin, Qiang Xu, Qiang Xu

Connect to this object online.